Abstract : Biologics, including certain vaccines, have been recognized since the nineteenth century. The Food and Drug Administration (FDA) of the United States approved the first bacteria-generated biologic, human insulin, in 1982. Examples of biologics encompass vaccines like those for human papillomavirus, gene therapies, transplant tissues such as tendons and ligaments, blood and blood products like platelets, recombinant proteins like insulin, stem cell therapies for cancers or genetic disorders, and monoclonal antibodies used to combat cancer and treat autoimmune diseases [3]. Despite being a longstanding concept, biologics have evolved, especially since the 1980s when modern recombinant DNA technology was employed in their production for treating various ailments.
Keywords :
Cite : Telang, U., & Khanna, A. (2024). Major Biosimilars In The Market Contributing To The Economy Of Pharma Industry In Us And The Impact Of Covid-19 On Biosimilars Market Globally (1st ed., pp. 62-66). Noble Science Press. https://doi.org/10.52458/9788197040887.2024.eb.ch-14
References :
Declerck, P., Danesi, R., Petersel, D., & Jacobs, I. (2017). The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs, 77, 671-677.
Konstantinidou, S., Papaspiliou, A., & Kokkotou, E. (2020). Current and future roles of biosimilars in oncology practice. Oncology letters, 19(1), 45-51.
Kim, H., Alten, R., Avedano, L., Dignass, A., Gomollón, F., Greveson, K., ... & Jeong, J. H. (2020). The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs, 80, 99-113.
